<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04655144</url>
  </required_header>
  <id_info>
    <org_study_id>20200788</org_study_id>
    <nct_id>NCT04655144</nct_id>
  </id_info>
  <brief_title>Dexamethasone for Post Uterine Artery Embolization Pain</brief_title>
  <acronym>Dex-Fib</acronym>
  <official_title>Intra-Arterial Dexamethasone for the Alleviation of Pain and Postembolization Syndrome Following Uterine Artery Embolization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to investigate if administration steroids (anti-inflammatory&#xD;
      medication) via the uterine arteries during uterine fibroid embolization (A non surgical&#xD;
      procedure for treating uterine fibroids by blocking their blood supply) can help reduce the&#xD;
      pain, nausea, vomiting, and general feeling of weakness following the procedure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain scores using the VAS Questionnaire</measure>
    <time_frame>Day 7</time_frame>
    <description>Pain is measured using a modified Visual Analogue Score (VAS), which has a total score ranging from 0 (no pain at all) to 10 (worst pain).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of post-embolization syndrome symptoms</measure>
    <time_frame>Day 7</time_frame>
    <description>Post embolization Syndrome (PES) symptomatology will be assessed using a PES survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in uterine fibroid volume</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>As evaluated via magnetic Resonance Imaging (MRI) using volumetric software</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in symptoms</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Change in participant symptoms will be assessed using the Uterine Fibroid Embolization (UFE) Quality of Life and Symptomatology Survey with a total subsection score ranging from 8-40 with the higher score indicating a patient-perceived improvement in symptomatology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Change in participant quality of life will be reported using the Uterine Fibroid Embolization (UFE) Quality of Life and Symptomatology Survey with a total subsection score ranging from 0-6 with the highest score indicating the best positive response.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Leiomyoma</condition>
  <arm_group>
    <arm_group_label>Dexamethasone Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 5mg dexamethasone will be administered into each uterine artery (10mg total) prior to uterine artery embolization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A volume of normal saline, equal to the total volume delivered in the Dexamethasone Arm, will be administered into each uterine artery prior to uterine artery embolization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone delivered to the uterine arterial bed, prior to embolization.</description>
    <arm_group_label>Dexamethasone Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline delivered to the uterine arterial bed, prior to embolization.</description>
    <arm_group_label>Saline Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women who meet criteria to undergo uterine fibroid embolization for symptomatic&#xD;
             fibroids.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently pregnant or actively attempting to conceive&#xD;
&#xD;
          -  Those deemed mentally impaired to make their own medical decisions&#xD;
&#xD;
          -  Previous documented allergy to dexamethasone&#xD;
&#xD;
          -  Those currently taking daily steroids for any reason&#xD;
&#xD;
          -  Those with diabetes or deemed to be pre-diabetic&#xD;
&#xD;
          -  Those with contraindications for angiography&#xD;
&#xD;
          -  Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prasoon Mohan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lia Quezada, MD</last_name>
    <phone>305-243-2210</phone>
    <email>LQuezada@med.miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lia Quezada</last_name>
      <phone>305-243-2210</phone>
      <email>LQuezada@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Prasoon Mohan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Prasoon Mohan</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Fibroids</keyword>
  <keyword>Leiomyoma</keyword>
  <keyword>post-embolization pain</keyword>
  <keyword>dexamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

